Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
End stage kidney disease
Do you dose ESAs via an intravenous or subcutaneous route for hospitalized patients with ESKD and anemia?
Related Questions
How do you approach the management of a patient with nonoliguric ESKD, massive proteinuria, and hypoalbuminemia who is already on an ACE inhibitor?
Would you continue spironolactone in a patient who has recently progressed to ESKD on HD with oliguria and was diagnosed with primary hyperaldosteronism years ago?
How long do you recommend waiting before repeating a serum electrolyte panel after the conclusion of an intermittent hemodialysis session to ensure accurate results are obtained?
Would you use argatroban or citrate catheter lock in a patient with ESKD and HITT?
Are there situations when you a 1K dialysis bath as a long-term outpatient prescription for patients with ESKD?
Do you prefer automated peritoneal dialysis during the day or night for a hospitalized patient with ESKD on PD?
Do you take any special considerations for a patient with ESKD who has an ileostomy/colostomy and wishes to start peritoneal dialysis?
Do you use the same hemoglobin target as an ESKD patient for an outpatient with AKI-D who has been receiving dialysis for more than 30 days and is prescribed an ESA?
Do you favor peritoneal dialysis over hemodialysis in patients with an LVAD who have ESKD?
How do you determine when it is appropriate to transition a patient back to peritoneal dialysis after they were switched to hemodialysis due to PD catheter removal for refractory peritonitis, once the infection has been treated?
